Navigation Links
Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/5/2008

214,124 204,659

Accumulated deficit (127,409) (67,445)

Accumulated other comprehensive income 114 1,314

Total stockholders' equity 87,372 139,065

Total liabilities and stockholders'

equity $115,222 $167,173

SAVIENT PHARMACEUTICALS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenues:

Product sales, net $499 $2,532 $1,958 $12,011

Other revenues 43 48 125 124

542 2,580 2,083 12,135

Cost and expenses:

Cost of goods sold 303 - 855 288

Research and

development 10,875 12,135 37,762 36,154

Selling, general and

administrative 7,563 6,782 27,277 21,311

18,741 18,917 65,894 57,753

Operating loss from

Continuing operations (18,199) (16,337) (63,811) (45,618)

Investment income, net 340 2,159 1,704 6,829

Other expense, net (148) (93) (460) (424)

Loss from continuing

operations before

income taxes (18,007) (14,271) (62,567) (39,213)

Income tax expense

(benefit) (863) 294 (3,673) (7,173)

Loss from continuing

operations (17,14
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Savient Submits Biologics License Application (BLA) for pegloticase
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
4. Onyx Pharmaceuticals to Present at the 2008 Credit Suisse Health Care Conference
5. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
6. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
7. Anadys Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
8. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
9. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
10. OncoMed Pharmaceuticals Completes Series B Financing
11. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Research and ... addition of Jain PharmaBiotech,s new report ... to their offering. The scope ... in situ hybridization (FISH), comparative genomic hybridization ... application of nanobiotechnology, microarrays, real-time polymerase chain ...
(Date:9/2/2015)... 2, 2015 Australian prostate cancer technology company ... science prize recognising ,outstanding, science that uses its patented ... launch a novel prostate cancer diagnostic test known as ... consortium taking out the peer-reviewed Australian Museum Eureka Science ... This prize is awarded for ground breaking ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficiency of their entire waste to energy process and continue to contribute to ... Major Upgrade , Temarry’s Waste to Energy process has been operating at their ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... July 17 Encorium Group, Inc. (Nasdaq: ... research organization (CRO) that provides design, development, and management ... of the world,s leading pharmaceutical companies, today announced that ... Company,s U.S. business to Pierrel Research USA, Inc., a ...
... 16 Nile Therapeutics, Inc. (Nasdaq: NLTX ), a ... patients, today announced that it has completed a private placement of ... stock for aggregate gross proceeds of approximately $3.4 million. Riverbank Capital ... agent for the transaction. , , ...
... - Introductory Webinar, July 21st, 11am EDT, ... September 15-16, San Diego,CA , ChemAxon, a ... Excel. The add-in for Microsoft Excel(R),brings all of the capabilities and ... will be introduced at a free webinar,on July 21st and Workshop ...
Cached Biology Technology:Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 2Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 3Encorium Group Completes Sale of its U.S. Business to Pierrel Research USA; Announces Management Changes 4Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 2Nile Therapeutics, Inc. Completes $3.4 Million Private Placement 3ChemAxon Launches JChem for Excel 2
(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/10/2015)... and TELTOW, Germany , August 10, ... (SMI), a world leader in Eye Tracking Technology for ... its OEM Eye Tracking Platform for integration into all ... contains reference designs for seamless integration of eye tracking ... reality HMDs and augmented reality smart glasses. Omnivision,s leading ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... York City’s smoking rate has plummeted since a comprehensive ... findings issued today in the national Centers for Disease ... The 2006 rate was nearly 20% lower than the ... smokers. The City’s rate for 2006 is the lowest ...
... of California, San Diego (UCSD) Skaggs School of Pharmacy ... a human vaccine to prevent against Human Cytomegalovirus (hCMV) ... of herpes virus, is the leading viral cause of ... compromised immune systems. The body’s natural immunity doesn’t ...
... are the bad guys that help bacterial pathogens do their ... system. In essence, they knock down the front door ... researchers at the University of California, San Diego (UCSD) School ... effector protein called YpkA, one of several effectors of the ...
Cached Biology News:Smoking rate has plummeted in New York City 2New vaccine prevents CMV infection and disease in mice 2New vaccine prevents CMV infection and disease in mice 3How plague-causing bacteria disarm host defense 2